Future University In Egypt (FUE)
Future University is one of most promising private universities in Egypt. Through excellence in teaching, research and service, Future University strives to provide a comprehensive, high-quality education that prepares our graduates to be future leaders.
mainLogo
Altagamoa Al Khames, Main centre of town, end of 90th Street
New Cairo
Egypt

Youmna Ibrahim

Basic information

Name : Youmna Ibrahim
Title: Lecturer
Google Schoolar Link
Personal Info: Youmna Ibrahim, Assistant Lecturer of Pharmaceutical Chemsirty - Department of pharmaceutical chemistry. She has a bachelor degree in Pharmaceutical Sciences from Future University in Egypt in 2011. View More...

Education

Certificate Major University Year
PhD 2022
Masters 2017
Bachelor 2011

Researches /Publications

New quinazolinone‐based derivatives as DHFR/EGFR‐TK inhibitors: Synthesis, molecular modeling simulations, and anticancer activity

Yomna Ibrahim Hassan El Gazzar

Heba R. Ghaiad; Ahmed M. El Kerdawy: Riham F. George;Hanan H. Georgey;Hussein I. EL-Subbagh

18/10/2022

https://onlinelibrary.wiley.com/doi/full/10.1002/ardp.202200417

Download PDF
Thiazolo [4, 5-d] pyridazine analogues as a new class of dihydrofolate reductase (DHFR) inhibitors: Synthesis, biological evaluation and molecular modeling study.

Yomna Ibrahim Hassan El Gazzar

Dalal A.Abou El Ellab,Deena S.Lasheen

01/10/2017

A new series of 1,3-thiazoles and thiazolo[4,5-d]pyridazine both bearing the 2-thioureido function were designed, synthesized and evaluated for their in vitro DHFR inhibition and antitumor activities. Compound 26 proved to be the most active DHFR inhibitor (IC50 of 0.06 μM). Compound 4, 20 and 21 showed in vitro antitumor activity against a collection of cancer cell lines. Compound 26 proved lethal to HS 578T breast cancer cell line with IC50 value of 0.8 μM, inducing cell cycle arrest and apoptosis. Molecular modeling studies concluded that recognition with key amino acids Phe 31 and Arg 22 is essential for DHFR binding. The obtained model could be useful for the development of new class of DHFR inhibitors.

Download PDF
Synthesis, biological evaluation and molecular modeling study of new (1, 2, 4-triazole or 1, 3, 4-thiadiazole)-methylthio-derivatives of quinazolin-4 (3H)-one as DHFR inhibitors.

Yomna Ibrahim Hassan El Gazzar

Hanan H.Georgey,Shahenda M.El-Messery, Ghada S.Hassane

01/06/2017

A new series of 2-mercapto-quinazolin-4-one analogues was designed, synthesized and evaluated for their in vitro DHFR inhibition, antitumor and antimicrobial activity. Compound 17 proved to be the most active DHFR inhibitor with IC50 value of 0.01 μM, eight fold more active than methotrexate (MTX). Compounds 16 and 24 showed antitumor activity against human Caco2 colon and MCF-7 breast tumor cell lines with IC50 values of 25.4 and 9.5 μg/ml, respectively. Compounds 15, 20, 21 and 30 showed considerable activity against the Gram-positive bacteria Staphylococcus aureus while 24 and 30 proved active against Bacillus subtilis with a magnitude of potency comparable to the broad spectrum antibiotic Ciprofloxacin. Strong activity was observed for 13, 14, 19, 20 and 24 against Candida albicans and Aspergillus flavus. Compound 17 shared a similar molecular docking mode with MTX and made a critical hydrogen bond and arene-arene interactions via Ala9 and Phe34 amino acid residues, respectively.

Download PDF
Synthesis, biological evaluation and molecular modeling study of new (1, 2, 4-triazole or 1, 3, 4-thiadiazole)-methylthio-derivatives of quinazolin-4 (3H)-one as DHFR inhibitors

Yomna Ibrahim Hassan El Gazzar

Hanan H. Georgey, Shahenda M. El-Messery, Ghada S. Hassan,

01/06/2016

A new series of 2-mercapto-quinazolin-4-one analogues was designed, synthesized and evaluated for their in vitro DHFR inhibition, antitumor and antimicrobial activity. Compound 17 proved to be the most active DHFR inhibitor with IC50 value of 0.01 μM, eight fold more active than methotrexate (MTX). Compounds 16 and 24 showed antitumor activity against human Caco2 colon and MCF-7 breast tumor cell lines with IC50 values of 25.4 and 9.5 μg/ml, respectively. Compounds 15, 20, 21 and 30 showed considerable activity against the Gram-positive bacteria Staphylococcus aureus while 24 and 30 proved active against Bacillus subtilis with a magnitude of potency comparable to the broad spectrum antibiotic Ciprofloxacin. Strong activity was observed for 13, 14, 19, 20 and 24 against Candida albicans and Aspergillus flavus. Compound 17 shared a similar molecular docking mode with MTX and made a critical hydrogen bond and arene-arene interactions via Ala9 and Phe34 amino acid residues, respectively.

Download PDF

Follow us on

Visit the Faculty

ADS